Currently, there are 31.40M common shares owned by the public and among those 25.70M shares have been available to trade.
The company’s stock has a 5-day price change of -6.19% and -71.68% over the past three months. VINC shares are trading -83.56% year to date (YTD), with the 12-month market performance down to -78.58% lower. It has a 12-month low price of $0.18 and touched a high of $9.37 over the same period. VINC has an average intraday trading volume of 729.71K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.45%, -31.41%, and -81.03% respectively.
Institutional ownership of Vincerx Pharma Inc (NASDAQ: VINC) shares accounts for 32.77% of the company’s 31.40M shares outstanding.
It has a market capitalization of $6.89M and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$1.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.36% over the week and 13.23% over the month.
Earnings per share for the fiscal year are expected to increase by 59.79%, and 39.47% over the next financial year.
Looking at the support for the VINC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on January 14, 2022, with the firm’s price target at $25. Cantor Fitzgerald coverage for the Vincerx Pharma Inc (VINC) stock in a research note released on December 23, 2021 offered a Overweight rating with a price target of $25. SVB Leerink was of a view on November 01, 2021 that the stock is Outperform, while Laidlaw gave the stock Buy rating on September 13, 2021, issuing a price target of $30. B. Riley Securities on their part issued Buy rating on August 25, 2021.
